Author: Aaron Hata
APOBEC manuscript is published!
Hideko’s manuscript “Therapy-induced APOBEC3A drives evolution of persistent cancer cells” is now published in Nature! We show that lung cancer targeted therapies induced APOBEC3A, which drives evolution of drug tolerance and resistance. This was terrific collaborative effort with the Lawrence Group, Dyson Lab, Zou Lab, Ott Lab, Getz Lab, MGH Thoracic Oncology and many others.
Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, Langenbucher A, Monroe S, Su W, Cabanos HF, Siddiqui FM, Phan N, Jalili P, Timonina D, Bilton S, Gomez-Caraballo M, Archibald HL, Nangia V, Dionne K, Riley A, Lawlor M, Banwait MK, Cobb RG, Zou L, Dyson NJ, Ott CJ, Benes C, Getz G, Chan CS, Shaw AT, Gainor JF, Lin JJ, Sequist LV, Piotrowska Z, Yeap BY, Engelman JA, Lee JJK, Maruvka YE, Buisson R, Lawrence MS, Hata AN. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature. 2023 Jul 5. doi: 10.1038/s41586-023-06303-1. Online ahead of print. PMID: 37407818
CenterStage 2023
Aaron teamed up with ALK NSCLC advocate and patient Colleen Ziegler at CenterStage 2023 at the MFA to highlight the importance of “bedside-to-bench” research at the MGH Cancer Center.
Chendi – AACR poster
AACR Annual Meeting 2023: Chendi presents her posters “Chromatin modification driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer” and “Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer.”
Hideko – AACR poster
AACR Annual Meeting 2023: Hideko presents her poster “Epigenetic regulation of APOBEC3A mutagenesis and tumor evolution during targeted therapy in non-small cell lung cancer.”
Wafa passes PQE
Congratulations to Wafa for passing her Preliminary Qualifying Exam for the Harvard BBS Program today!
U Colorado visit
Aaron speaks at the University of Colorado Cancer Center. Thank you to Dr. Sabrina Spencer for hosting. A great opportunity to make new friends and reconnect with former colleagues and trainees!
Stimulating macrophages can augment targeted therapy responses
Check out a new manuscript “Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction” now posted to bioRxiv! This is the product of a terrific collaboration with the Weiskopf lab at MIT.
Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, Keddy C, Nicholson KS, Yoda S, Mente S, Sun Y, Soglia JR, Kohl NE, Porter JR, Shair MD, Zhu V, Davare MA, Hata AN, Pelish HE, Lin JJ. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer Discovery. 2023 Mar 1;13(3):598-615. doi: 10.1158/2159-8290.PMID: 36511802
